Loading...
ROCO
4743
Market cap940mUSD
Nov 12, Last price  
61.50TWD
Name

Oneness Biotech Co Ltd

Chart & Performance

D1W1MN
ROCO:4743 chart
P/E
—
P/S
249.50
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.82%
Rev. gr., 5y
54.32%
Revenues
118m
+35.89%
1,631,00059,093,0003,715,0008,597,0004,609,0005,479,0007,841,0005,703,0002,587,00018,856,00013,475,00041,605,00065,765,0001,065,554,00086,783,000117,926,000
Net income
-1.17b
L-11.25%
6,280,000953,00013,956,000-27,390,000276,253,000199,726,000-93,017,000-14,257,000-155,446,000-235,436,000-328,463,000-251,679,000-412,823,000359,975,000-1,312,867,000-1,165,147,000
CFO
-346m
L-18.14%
-102,299,000153,245,000-29,266,00024,153,000-89,262,000-150,980,000-142,345,000-108,540,000-165,268,000-5,123,000-213,252,000158,138,000-288,894,000-881,001,000-422,176,000-345,579,000
Dividend
Jun 16, 20230.1124 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.
URL
https://www.onenessbio.com/tc/index.htm
IPO date
Jun 19, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT